JP2010533737A5 - - Google Patents

Download PDF

Info

Publication number
JP2010533737A5
JP2010533737A5 JP2010517201A JP2010517201A JP2010533737A5 JP 2010533737 A5 JP2010533737 A5 JP 2010533737A5 JP 2010517201 A JP2010517201 A JP 2010517201A JP 2010517201 A JP2010517201 A JP 2010517201A JP 2010533737 A5 JP2010533737 A5 JP 2010533737A5
Authority
JP
Japan
Prior art keywords
vlp
protein
vzv
influenza
tegument
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010517201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010533737A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/070636 external-priority patent/WO2009012487A2/en
Publication of JP2010533737A publication Critical patent/JP2010533737A/ja
Publication of JP2010533737A5 publication Critical patent/JP2010533737A5/ja
Withdrawn legal-status Critical Current

Links

JP2010517201A 2007-07-19 2008-07-21 キメラ水痘帯状疱疹ウイルス−ウイルス様粒子 Withdrawn JP2010533737A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95070707P 2007-07-19 2007-07-19
US97059207P 2007-09-07 2007-09-07
US7183508P 2008-05-20 2008-05-20
PCT/US2008/070636 WO2009012487A2 (en) 2007-07-19 2008-07-21 Chimeric varicella zoster virus-virus like particles

Publications (2)

Publication Number Publication Date
JP2010533737A JP2010533737A (ja) 2010-10-28
JP2010533737A5 true JP2010533737A5 (enExample) 2011-08-11

Family

ID=40260107

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010517201A Withdrawn JP2010533737A (ja) 2007-07-19 2008-07-21 キメラ水痘帯状疱疹ウイルス−ウイルス様粒子

Country Status (14)

Country Link
US (1) US20110008838A1 (enExample)
EP (3) EP2176427A4 (enExample)
JP (1) JP2010533737A (enExample)
CN (1) CN101801411A (enExample)
CA (1) CA2693899A1 (enExample)
CY (1) CY1116583T1 (enExample)
DK (1) DK2540312T3 (enExample)
ES (1) ES2542644T3 (enExample)
HR (1) HRP20150758T1 (enExample)
HU (1) HUE025702T2 (enExample)
PL (1) PL2540312T3 (enExample)
PT (1) PT2540312E (enExample)
SI (1) SI2540312T1 (enExample)
WO (2) WO2009012487A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
PL2370099T3 (pl) 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania
EP2424980A1 (en) * 2009-05-01 2012-03-07 Redbiotec AG Recombinant virus-like particles encoded by multi-gene vector
PL222497B1 (pl) 2009-06-26 2016-08-31 Inst Biochemii I Biofizyki Pan Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej
WO2011003100A2 (en) 2009-07-02 2011-01-06 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
JP2013541528A (ja) 2010-09-21 2013-11-14 マサチューセッツ インスティテュート オブ テクノロジー ヒト適応haポリペプチド、ワクチン、およびインフルエンザの処置
JP6029586B2 (ja) 2010-10-04 2016-11-24 マサチューセッツ インスティテュート オブ テクノロジー 血球凝集素ポリペプチド、ならびにそれに関連する試薬および方法
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
EA033467B1 (ru) * 2011-01-31 2019-10-31 Univ Pennsylvania Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение
EP4241785B1 (en) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
RU2014117068A (ru) * 2011-09-30 2015-11-10 Новавакс, Инк. Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса
ES2728248T3 (es) 2012-01-24 2019-10-23 Univ Georgia Vacunas basadas en el virus paragripal 5
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
KR20150138184A (ko) * 2013-02-11 2015-12-09 노바백스, 인코포레이티드 호흡기 세포 융합 바이러스 및 인플루엔자를 위한 조합 백신
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
CA2996007A1 (en) 2015-09-03 2017-03-09 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
JP7317796B2 (ja) 2017-07-24 2023-07-31 ノババックス,インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
CN120227451A (zh) 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CN110237248A (zh) * 2019-07-01 2019-09-17 大连民族大学 一种带状疱疹疫苗的制备方法
BR112022017852A2 (pt) 2020-03-09 2022-11-01 Dynavax Tech Corp Vacinas para herpes zoster compreendendo um agonista de tlr9
MX2022016502A (es) * 2020-06-17 2023-03-13 Meissa Vaccines Inc Proteinas quimericas de rsv y coronavirus, composiciones inmunogenicas y metodos de uso.
GB202017649D0 (en) * 2020-11-09 2020-12-23 Autolus Ltd Polypeptide
KR102680105B1 (ko) * 2021-05-17 2024-07-02 대한민국 코로나19 바이러스 및 인플루엔자 h1n1 바이러스에 대한 바이러스 유사입자 및 이의 용도
KR20250143785A (ko) * 2023-01-19 2025-10-02 시아먼 유니버시티 수두-대상포진 바이러스의 ge 및 gi 융합 단백질 및 이의 용도
CN119080948B (zh) * 2023-04-17 2025-05-27 北京康乐卫士生物技术股份有限公司 带状疱疹病毒疫苗的嵌合抗原及其应用
CN120418435A (zh) * 2023-11-13 2025-08-01 石药集团巨石生物制药有限公司 一种抵抗带状疱疹的mRNA疫苗及其制备方法
CN120020142A (zh) * 2023-11-20 2025-05-20 上海蓝鹊生物医药有限公司 一种vzv抗原变体、核酸、药物组合物及其应用
WO2025180455A1 (en) * 2024-02-27 2025-09-04 Therorna Inc. A circular rna vaccine against herpes zoster virus and the use thereof
CN119684476B (zh) * 2025-02-21 2025-05-06 中国医学科学院医学生物学研究所 一种抗水痘-带状疱疹病毒单克隆抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US20040121465A1 (en) 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
MXPA04010902A (es) * 2004-11-03 2006-05-08 Alvaro Raul Lara Rodriguez Vacuna recombinante a partir de las proteinas ge, gi y gb del virus de varicela zoster como tratamiento y prevencion de esclerosis multiple.
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
KR101359723B1 (ko) * 2005-10-18 2014-02-05 노바백스, 인코포레이티드 기능성 인플루엔자 바이러스 유사 입자들

Similar Documents

Publication Publication Date Title
JP2010533737A5 (enExample)
Krammer et al. Trichoplusia ni cells (High FiveTM) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines
JP2013216685A5 (enExample)
JP2004501647A5 (enExample)
Xu et al. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine
JP2019011344A5 (enExample)
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
Wiersma et al. Developing universal influenza vaccines: hitting the nail, not just on the head
JP2015119730A5 (enExample)
WO2017136575A1 (en) Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
JP2012095652A5 (enExample)
JP2013533745A5 (enExample)
JP2010533001A5 (enExample)
JP2014221052A5 (enExample)
MX392585B (es) Particulas similares al virus de la influenza quimericas que comprenden hemaglutinina.
WO2010003225A8 (en) Influenza virus-like particles (vlps) comprising hemagglutinin
JP2016521553A5 (enExample)
WO2010118424A3 (en) Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
MY161965A (en) New influenza virus immunizing epitope
JP7577101B2 (ja) 異種エピトープ及び/又は改変された成熟切断部位を有するインフルエンザヘマグルチニンの組成物
CA2863981A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
Chen et al. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic
HK1203522A1 (en) Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses
Liu et al. Association of influenza virus matrix protein with ribonucleoproteins may control viral growth and morphology